TRANSCOV-19: Transfusion and COVID-19
Alsace was particularly and early on affected by SARS-CoV-2 and quickly implemented a reduction in scheduled admissions and non-urgent surgical interventions, making it possible to reduce requests for labile blood products linked to non-urgent surgical procedures. as has been reported in the literature; the population containment measures also led to a major reduction in traffic - and consequently accidents on the public roads. At the same time, other demands for blood products related to activities such as onco-hematology were little affected. Finally, the blood banks have adapted their collection procedure.
To answer these questions, we propose to conduct a retrospective study over two parallel periods of 2019 and 2020 of the consumption of blood products on the one hand and the availability of stocks on the other hand.
|Condition or Disease||Intervention/Treatment||Phase|
Primary Outcome Measures
- Retrospective study of the consumption of blood products on the one hand and the availability of stocks on the other hand. [Files analysed retrospectively from from February 24 to May 31, 2019 and from February 24 to May 31, 2020 will be examined]]
All admissions of adult patients to Strasbourg University Hospitals and all labile blood products consumed between February 24 and May 31 of 2019 and 2020
Refusal to participate in the study
Contacts and Locations
|1||Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg||Strasbourg||France||67091|
Sponsors and Collaborators
- University Hospital, Strasbourg, France
- Principal Investigator: Paul-Michel MERTES, MD, PhD, Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg
Study Documents (Full-Text)None provided.